| Timetable |
| Download Conference Program |
| Download All Abstracts |
| Zoom Access |
| Corporate Program |
Oral Sessions
Day 2, June 23（Mon.） 11:40-12:10
Room C (Top of Yaima)
- 2C-O1-1140
Quantitative Measurements of Circulating Ceramides as Markers for Cardiometabolic Disorders
(Duke-NUS)
oFederico Torta
Ceramides (Cer) are sphingolipids accumulating in human blood plasma during metabolic disorders, insulin resistance and diabetes. Monitoring levels of four circulating ceramides, Cer d18:1/16:0, Cer d18:1/18:0, Cer d18:1/24:0 and Cer d18:1/24:1 can predict the risk for cardiovascular disease (CVD) events and death. In a community effort, we compared measurements between 34 laboratories from 19 countries, utilizing mixtures of labelled authentic synthetic standards, to quantify by mass spectrometry four clinically used ceramide species in the NIST (National Institute of Standards and Technology) human blood plasma Standard Reference Material (SRM) 1950, as well as new suite of candidate plasma reference materials (RM 8231). We also present an online Solid Phase Extraction-Tandem Mass Spectrometry (SPE–MS/MS) methodology for ultrafast (∼15 seconds/sample) measurements of these ceramides in human plasma. The applicability of the novel methodology was demonstrated by testing the association of plasma ceramides with different outcomes in patients with type 2 diabetes.